GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a prominent player in the healthcare technology sector, focusing on imaging, advanced visualization solutions, and patient care. The company is set to release its fourth-quarter 2024 earnings on February 13, 2025. Wall Street anticipates earnings per share (EPS) of $1.26 and revenue of $5.33 billion for this quarter.
In the previous quarter, GEHC reported an adjusted EPS of $1.14, exceeding the Zacks Consensus Estimate by 7.55%. This quarter, analysts from Zacks Investment Research project a 6.8% increase in EPS compared to the same period last year. The company's revenue is expected to rise by 2.4% from the previous year's quarter, reaching $5.33 billion.
Despite challenges in China, GEHC is likely to benefit from strong demand in the U.S. and effective backlog execution. The pharmaceutical sector is expected to be a key driver of the company's performance. Additionally, product innovation and operational efficiencies are anticipated to contribute positively to GEHC's results.
GEHC's financial metrics provide insight into its market position. The company has a price-to-earnings (P/E) ratio of 23.73, indicating the price investors are willing to pay for each dollar of earnings. The price-to-sales ratio is 2.03, suggesting investors pay slightly over two times the company's sales per share.
The company's enterprise value to sales ratio is 2.40, reflecting its total valuation compared to sales. GEHC's enterprise value to operating cash flow ratio is 22.48, showing how its valuation compares to cash flow from operations. The debt-to-equity ratio is 1.29, indicating the proportion of debt used to finance assets relative to shareholders' equity. The current ratio of 1.23 suggests GEHC has a reasonable level of liquidity to cover short-term liabilities.
